3 results match your criteria: "Penn State Health Milton S. Hershey Medical Centre[Affiliation]"
Monkeypox: another pandemic in the making?
Proc (Bayl Univ Med Cent)
April 2023
Department of Medicine, Penn State Health Milton S. Hershey Medical Centre, Hershey, Pennsylvania.
Article Synopsis
- Monkeypox is a disease caused by the monkeypox virus, transmitted through contact with fluid secretions, and its symptoms start with fever and chills before developing into a rash.
- Diagnosis is done through a polymerase chain reaction test, and the treatment is mainly supportive care.
- The decline of the smallpox vaccine has led to increased susceptibility to monkeypox, which is now spreading globally, prompting the WHO to declare a public health emergency in July 2022 due to its rapid transmission and potential to evolve into a pandemic.
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Lancet Haematol
May 2021
Critical Care Department, APHP, Hôpital Saint-Louis, University of Paris, Paris, France.
Background: Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care.
Methods: This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecol Oncol
June 2019
The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer.
Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II-IV or recurrence after stage I disease.